Abstract
Objective
To evaluate whether tibolone had adverse effects on the prognosis of endometrial cancer
patients.
Methods
In this retrospective matched case–control study, out of 396 patients with endometrial
cancer from January 1997 to December 2002, 68 patients who underwent complete surgical
staging were identified as tibolone users (cases). For each case, one control as tibolone
non-user was matched for stage and grade of disease, in this order of priority (ratio
users: non-users, 1:1).
Results
There were no significant differences in age (p = 0.11), stage (p = 1.00), grade (p = 0.96) and treatment modality (p = 0.55) between two arms. The mean duration of follow-up for tibolone users and tibolone
non-users is 48.0 months and 54.4 months, respectively (p = 0.12). In tibolone users, a total of four patients recurred and two out of four patients
died of disease. In tibolone non-users, there were three recurrences and all of three
patients died of disease. There were no significant differences in disease free survival
(p = 0.52) and overall survival (p = 0.61) between two arms. And there was no significant difference in disease free survival
according to the duration of tibolone use (p = 0.14).
Conclusion
There was no evidence that tibolone had adverse effects on the disease free survival
and overall survival of endometrial cancer patients. So, tibolone could be used in
these patients.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to MaturitasAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
2002 Annual report of the Korea central cancer registry (2002.1-2002.12). Republic of Korea: Korea Central Cancer Registry, Ministry of Health and Welfare; 2003.
Annual report of gynecologic cancer registry program in Korean for 2002 (Jan. 1st, 2002-Dec. 31st, 2002). Kr J Obstet Gynecol 2004; 6:1029-71.
- Endometrial cancer in premenopausal women 45 years and younger.Obstet Gynecol. 1995; 85: 504-508
- Estrogen replacement in surgical stage I and II endometrial cancer survivors.Am J Obstet Gynecol. 1996; 175: 1195-1200
- ACOG committee opinion-hormone replacement therapy in women treated for endometrial cancer.Int J Gynaecol Obstet. 2001; 73: 283-284
- Risk factors among young women with endometrial cancer: a Danish case–control study.Am J Obstet Gynecol. 2000; 182: 23-29
- Characteristics and outcome of endometrial carcinoma patients age 45 years and younger.Am J Clin Oncol. 2000; 23: 476-480
- Profile of women 45 years of age and younger with endometrial cancer.Obstet Gynecol. 1998; 91: 349-354
- The prevalence of hot flash and associated variables among perimenopausal women.Res Nurs Health. 1985; 8: 261-268
- Effects of natural menopause, hysterectomy, and oophorectomy on lumbar spine and femoral neck bone densities.Obstet Gynecol. 1988; 72: 631-638
- Premenopausal hysterectomy and cardiovascular disease.Am J Obstet Gynecol. 1981; 139: 58-61
SEER Cancer Statistics Review 1975–2000. (http://seer.cancer.gov/csr/1975_2000).
- Carcinoma of the corpus uteri.J Epidemiol Biostat. 2001; 6: 47-86
North American Menopause Society (NAMS) 2003. Estrogen and progesterone use in the peri-and postmenopausal women: September 2003 position statement of the North American Menopause Society. Menopause 2003; 10:497–506.
- Estrogen replacement therapy in the patient treated for endometrial cancer.Obstet Gynecol. 1986; 67: 326-330
- Estrogen replacement therapy following treatment for stage I endometrial carcinoma.Gynecol Oncol. 1990; 36: 189-191
- Estrogen replacement in surgical stage I and II endometrial cancer survivors.Am J Obstet Gynecol. 1996; 175: 1195-1200
- Estrogen replacement therapy in endometrial cancer patients: a matched control study.Obstet Gynecol. 2001; 97: 555-560
- Hormone replacement therapy for survivors of breast and endometrial cancer.Curr Oncol Rep. 2002; 4: 152-158
- Tibolone: clinical recommendations and practical guidelines a report of the International Tibolone Consensus Group.Maturitas. 2005; 51: 21-28
- A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability.Climacteric. 2002; 5: 60-69
- Long-term effects of tibolone on the genital tract in postmenopausal women.Br J Obstet Gynaecol. 1999; 106: 954-959
- The effects of tibolone on mood and libido.Menopause. 2002; 9: 162-170
- Tibolone versus conjugated estrogens and sequential progestogen in the treatment of climacteric complaints.Maturitas. 1996; 23: 35-48
- Randomized, double-blind, 2-year comparison of tibolone with 17β-estradiol and norethindrone acetate in preventing postmenopausal bone loss.Osteoporos Int. 2002; 13: 241-248
- Effects of tibolone and a continous combined HRT regimen on mammographic breast density.Am J Obstet Gynecol. 2002; 186: 717-722
- Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women.Fertil Steril. 2004; 81: 617-623
- Progestogenic effects of tibolone on human endometrial cancer cells.J Clin Endocrinol Metab. 2003; 88: 2327-2334
- Molecular portrait of the progestagenic and estrogenic actions of tibolone: behavior of cellular networks in response to tibolone.J Clin Endocrinol Metab. 2005; 90: 973-983
- Endometrial cancer and hormone-replacement therapy in the Million Women Study.Lancet. 2005; 365: 1543-1551
Article info
Publication history
Accepted:
March 30,
2006
Received in revised form:
March 29,
2006
Received:
December 13,
2005
Identification
Copyright
© 2006 Elsevier Ireland Ltd. Published by Elsevier Inc. All rights reserved.
